关键词: Anterior segment Corneal diseases Corneal imaging diagnosis Corneal neovascularization Optical coherence tomography angiography

Mesh : Corneal Neovascularization / diagnosis Humans Tomography, Optical Coherence / methods Animals Fluorescein Angiography / methods Cornea / blood supply pathology diagnostic imaging Microscopy, Confocal

来  源:   DOI:10.1016/j.exer.2024.109930

Abstract:
Corneal neovascularization (CoNV) is a vision-threatening ocular disease commonly secondary to infectious, inflammatory, and traumatic etiologies. Slit lamp photography, in vivo confocal microscopy, angiography, and optical coherence tomography angiography (OCTA) are the primary diagnostic tools utilized in clinical practice to evaluate the vasculature of the ocular surface. However, there is currently a dearth of comprehensive literature that reviews the advancements in imaging technology for CoNV administration. Initially designed for retinal vascular imaging, OCTA has now been expanded to the anterior segment and has shown promising potential for imaging the conjunctiva, cornea, and iris. This expansion allows for the quantitative monitoring of the structural and functional changes associated with CoNV. In this review, we emphasize the impact of algorithm optimization in anterior segment-optical coherence tomography angiography (AS-OCTA) on the diagnostic efficacy of CoNV. Through the analysis of existing literature, animal model assessments are further reported to investigate its pathological mechanism and exhibit remarkable therapeutic interventions. In conclusion, AS-OCTA holds broad prospects and extensive potential for clinical diagnostics and research applications in CoNV.
摘要:
角膜新生血管形成(CoNV)是一种威胁视力的眼部疾病,通常继发于感染性疾病,炎症,和创伤性病因。裂隙灯摄影,体内共聚焦显微镜,血管造影,光学相干断层扫描血管造影(OCTA)是临床实践中用于评估眼表脉管系统的主要诊断工具。然而,目前缺乏全面的文献来回顾CoNV给药的成像技术的进步.最初设计用于视网膜血管成像,OCTA现已扩展到前段,并显示出结膜成像的潜力,角膜,还有虹膜.这种扩展允许定量监测与CoNV相关的结构和功能变化。在这次审查中,我们强调眼前节光学相干断层扫描血管造影(AS-OCTA)中算法优化对CoNV诊断效能的影响.通过对现有文献的分析,进一步报道了动物模型评估以研究其病理机制并表现出显着的治疗干预措施。总之,AS-OCTA在CoNV的临床诊断和研究应用中具有广阔的前景和广阔的潜力。
公众号